Neuromuscular

Children with Spinal Muscle Atrophy Treated Presymptomatically With Nusinersen Are Sitting Independently and Walking

Saturday, October 06, 2018—Infants with spinal muscle atrophy (SMA), who were diagnosed through genetic testing and treated with nusinersen (Spinraza; Biogen, Cambridge, MA) prior to the onset of sympto…

Positive Results for Risdiplam—An Investigational Oral Agent for Spinal Muscle Atrophy

Wednesday, October 03, 2018—Results from clinical trials of risdiplam (RG7916; Genentech, South San Francisco, CA) for treatment of infants with spinal muscle atrophy (SMA) were presented at the World Mu…

Hometown Highlights: Introducing Hometown Highlights

Stephen M. Gollomp, MD

October 2018—In this new column, we feature content from presenters at the 2018-2019 Philadelphia Neurological Society meetings.

Persistent Idiopathic Isolated Hypoglossal Nerve Palsy

Eric A. Nelson; Dennis Keselman; Aron Z. Pollack, MD; and Steven Mandel, MD

October 2018—Could this rare condition be related to vascular compression?

Neurostimulation of Spinal Cord Restores Assisted Ambulation

Thursday, September 27, 2018—September 27, 2018 -- In a case study published in Nature Medicine(September 26, 2018), a combined approach of spinal cord stimulation and physical therapy has succe…

New Functional Outcome Measure for Charcot-Marie-Tooth Disease

Wednesday, September 26, 2018—The Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM) is a new performance-based measure designed to assess functional abilities in adults with CMT that has now been sh…

Cognitive Effects of Amyotrophic Lateral Sclerosis Increase as Disease Progresses

Wednesday, September 12, 2018—Although it is often referred to as a neurologic disease that attacks the body and not the mind, cognitive effects in amyotrophic lateral sclerosis (ALS) exist and have been r…

FDA Approves of Oral Suspension of Riluzole for Patients With Amyotrophic Lateral Sclerosis

Monday, September 10, 2018—The Food and Drug Administration (FDA) has approved a new formulation of riluzole (Tiglutek; ITF Pharma, Berwyn, PA) for patients with amyotrophic lateral sclerosis (ALS). Thi…